So Yeon Kim, MD
Assistant ProfessorCards
About
Research
Publications
2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Cortellini A, Santo V, Brunetti L, Garbo E, Pinato D, La Cava G, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Alessi J, Montrone M, Owen D, Ramella S, Signorelli D, Fidler M, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D’Alessio A, Banna G, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e012423. PMID: 41022528, PMCID: PMC12481261, DOI: 10.1136/jitc-2025-012423.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerArea under the curveLong-term outcomesRisk of deathPD-L1Eastern Cooperative Oncology Group performance statusNon-cancer-related factorsLong-term follow-upImpact of smoking statusFirst-line pembrolizumabCell lung cancerProtective rolePrimary risk factorMetastatic burdenPerformance statusCancer prognosticationEarly mortalityLung cancerC-indexFollow-upGlobal RegistryPrognostic trendPembrolizumabBaseline variablesLasering in on Uncommon EGFR Mutations
Kim S, Politi K, Goldberg S. Lasering in on Uncommon EGFR Mutations. Journal Of Thoracic Oncology 2025, 20: 1148-1151. PMID: 40914593, DOI: 10.1016/j.jtho.2025.06.014.Commentaries, Editorials and LettersSmall Cell Lung Cancer
Kim S, Park H, Chiang A. Small Cell Lung Cancer. JAMA: The Journal Of The American Medical Association 2025, 333: 1906-1917. PMID: 40163214, DOI: 10.1001/jama.2025.0560.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThis study investigates the treatment advancements for small cell lung cancer, showing that combining chemotherapy, radiotherapy, and immunotherapy improves survival rates, highlighting the importance of early diagnosis and tailored therapy.Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders
Fletcher K, Machaalani M, Chehade R, Nassar A, Nawfal R, Manos M, Menzies A, Aboubakar-Nana F, Hassel J, Pinato D, Johnson A, Olsson-Brown A, Carlino M, Malgeri A, Cortellini A, Singh A, Parikh K, Kim S, Naqash A, Long G, Challa P, Choueiri T, Sharon E, Shah S, Johnson D. Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders. JAMA Network Open 2025, 8: e2513727. PMID: 40465294, PMCID: PMC12138719, DOI: 10.1001/jamanetworkopen.2025.13727.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsNeurological autoimmune disordersImmune-related adverse eventsMyasthenia gravisCohort studyCheckpoint inhibitorsMultiple sclerosisAutoimmune disordersEfficacy of immune checkpoint inhibitorsStudies of immune checkpoint inhibitorsTreated with immune checkpoint inhibitorsControl cohortCases of Lambert-Eaton myasthenic syndromeICI outcomesImmune checkpoint inhibitor treatmentMulticenter retrospective cohort studyControl cohort of patientsLambert-Eaton myasthenic syndromeFatal casesAutoimmune neurological disordersCohort of patientsRetrospective cohort studyParkinson's diseaseICI therapyClinical characteristicsComparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab
Cortiula F, Kutiel T, Hsu M, Hendriks L, Nassar A, Moskovitz M, Kim S, Mirsky M, Jayakrishnan R, Bortolot M, Saddi J, Borghetti P, Chung M, Filippi A, De Ruysscher D, Bar J. Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab. European Journal Of Cancer 2025, 219: 115302. PMID: 39987799, DOI: 10.1016/j.ejca.2025.115302.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungChemoradiotherapyDisease ProgressionFemaleHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsProgression free survivalImmune checkpoint blockersConcurrent chemoradiationMedian OSOverall survivalDisease progressionNo significant OS differenceUnresectable stage III NSCLCComparative efficacyICB-based therapyImmunotherapy-based treatmentsSignificant OS differenceStage III NSCLCMulticenter retrospective studyCheckpoint blockersDurvalumab treatmentRelapsed NSCLCUnresectable NSCLCIII NSCLCOS benefitFree survivalOS differencePost-chemoradiationSystemic therapyConsecutive patientsDeterminants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi J, Montrone M, Owen D, Signorelli D, Fidler M, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika N, Napolitano A, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Rogado J, Moliner L, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e010674. PMID: 39904562, PMCID: PMC11795382, DOI: 10.1136/jitc-2024-010674.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerProgrammed cell death ligand 1Eastern Cooperative Oncology Group performance statusData cut-offLong-term efficacyIndividual patient-level dataMedian OSPembrolizumab monotherapySurvival rateProgressive diseaseDiscontinued treatment due to progressive diseaseTreated with first-line pembrolizumabClinical trialsPredictors of 5-year survivalFirst-line pembrolizumab monotherapyCell death ligand 1Pre-existing autoimmune diseaseFirst-line pembrolizumabKEYNOTE-024 trialPD-L1 TPSPermanently discontinue treatmentDeath-ligand 1Efficacy of pembrolizumabMedian Follow-Up
2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
Nassar A, El Zarif T, Khalid A, Rahme S, Zhong C, Kwak L, Salame M, Farhat E, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana F, Kaldas D, Naqash A, Sharon E, LeBoeuf N, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks J, Linnoila J, Hamnvik O, Mouhieddine T, Marron T, Parikh K, McKay R, Dilling T, Choueiri T, Adib E, Najem E, Kim S, Sonpavde G. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal For ImmunoTherapy Of Cancer 2024, 12: e008724. PMID: 38448038, PMCID: PMC10916116, DOI: 10.1136/jitc-2023-008724.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsImmune checkpoint inhibitorsTime to next treatmentNon-small cell lung cancerImmune checkpoint inhibitor initiationParaneoplastic syndromeOverall survivalCohort 1Checkpoint inhibitorsSolid tumorsPatients treated with immune checkpoint inhibitorsInterruption of ICIsMetastatic non-small cell lung cancerSafety of immune checkpoint inhibitorsTreated with immune checkpoint inhibitorsType of immune checkpoint inhibitorCohort 2Immune checkpoint inhibitor therapyKaplan-Meier methodCell lung cancerTime to exacerbationConcurrent chemotherapyICI initiationImmunosuppressive therapyMedian age
2023
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, Delasos L, Hicks J, Aldea M, Minuti G, Hines J, Aredo J, Dennis M, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess J, Kim S, Goldberg S, Li M, Wang Q, Qing Y, Ni Y, Truong M, Lee R, Ricciuti B, Alessi J, Wang J, Resuli B, Landi L, Tseng S, Nishino M, Digumarthy S, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan A, Blumenschein G, Zhang J, Owen D, Blakely C, Mountzios G, Shu C, Bestvina C, Garassino M, Marrone K, Gray J, Patel S, Cummings A, Wakelee H, Wolf J, Scagliotti G, Cappuzzo F, Barlesi F, Patil P, Drusbosky L, Gibbons D, Meric-Bernstam F, Lee J, Heymach J, Hong D, Heist R, Awad M, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discovery 2023, 13: 1556-1571. PMID: 37068173, PMCID: PMC11024958, DOI: 10.1158/2159-8290.cd-22-1420.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerClinical outcomesPatient stratificationRas gene alterationsInferior clinical outcomesCell lung cancerEarly disease progressionPoor clinical outcomesTumor suppressor genePrognostic subgroupsCombination therapyInferior outcomesIndividual tumorsGene alterationsCo-mutationsClinical outcome predictionDNA damage response/repairLung cancerGenomic alterationsSuppressor geneDisease progressionInhibitor efficacyTreatment personalizationPatients
2022
Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, C. P, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clinical And Research Reports 2022, 3: 100381. PMID: 36082279, PMCID: PMC9445394, DOI: 10.1016/j.jtocrr.2022.100381.Peer-Reviewed Original ResearchWhole transcriptome sequencingTranscriptome sequencingSplice siteMet stabilityDonor splice siteNext-generation sequencingTranscriptomic levelSplicing alterationsEnrichment analysisJunction pathwayPoint mutationsPotential therapeutic targetGenomic alterationsRNA expressionSequencingGene signaturePathwayMutational burdenGenomic profilingSynergistic increaseExpressionMost alterationsCheckpointTherapeutic targetSingle-sample gene
2021
Seroconversion rates following COVID-19 vaccination among patients with cancer
Thakkar A, Gonzalez-Lugo J, Goradia N, Gali R, Shapiro L, Pradhan K, Rahman S, Kim S, Ko B, Sica R, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein Y, Wolgast L, Verma A, Halmos B. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021, 39: 1081-1090.e2. PMID: 34133951, PMCID: PMC8179248, DOI: 10.1016/j.ccell.2021.06.002.Peer-Reviewed Original ResearchConceptsSeroconversion ratesFDA-approved COVID-19 vaccinesIgG titersImmunogenicity of COVID-19 vaccinesImmune checkpoint inhibitor therapyCOVID-19 vaccineSeroconversion post-vaccinationCheckpoint inhibitor therapyAnti-CD20 therapyStem cell transplantationAnti-spike IgG titersRate of seroconversionMRNA-based vaccinesPassive immunization strategiesLow IgG titersImmunosuppressed cohortsImmunosuppressive therapyInhibitor therapyHormone therapyCell transplantationHematologic malignanciesSolid tumorsProphylactic strategiesCOVID-19 infectionSARS-CoV-2 spike protein
Academic Achievements & Community Involvement
Clinical Care
Overview
So Yeon Kim, MD, is a medical oncologist who cares for patients with lung cancer, an area that she says is changing rapidly, thanks to new drugs in the past decade, targeted treatments, and immunotherapies that have led to significant improvements in outcomes even in people with advanced forms of the disease.
“I always knew I wanted to do something to help people,” Dr. Kim says. “I ultimately chose oncology because I enjoyed the long-term relationships I was able to build with patients and families. I really enjoy working with cancer patients because they are among the most resilient and courageous people, who continue to fight against a disease that still has many more problems to solve.”
Dr. Kim is working with colleagues toward personalizing cancer treatment for all patients with carefully selected treatment options based on the tumor’s “molecular fingerprint,” she says. “At Yale, there is a lot of ongoing scientific collaboration between clinicians and researchers that is helping bring the latest scientific discoveries to patients with the goal of improving their outcomes.”
An assistant professor at Yale School of Medicine, Dr. Kim focuses her research on both targeted treatment options and immunotherapy. “Oncology is a humbling field that can bring up more questions than answers, but I think that ultimately allows space for creativity and innovation,” she says. “While my research interests currently remain broad, I am interested in developing a more personalized approach to lung cancer care as we learn more about the science around what drives specific patients to respond better to certain therapies than to others,” she says.
Clinical Specialties
Fact Sheets
Lung Cancer
Learn More on Yale MedicineLung Cancer in Nonsmokers
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineNon-Small Cell Lung Cancer
Learn More on Yale Medicine
Yale Medicine News
News
News
- June 02, 2026
Yale Cancer Center Researchers and Trainees Present at 2026 ASCO Annual Meeting
- May 15, 2026
Yale Cancer Center Researchers Highlight Breakthroughs Across Cancer Care at ASCO 2026
- July 07, 2025
International Exchange Fosters Clinical and Research Collaboration
- June 06, 2025
Yale Cancer Center Researchers and Trainees Present at 2025 ASCO Annual Meeting
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.